EUR-Lex & EU Commission AI-Powered Semantic Search Engine
Modern Legal
  • Query in any language with multilingual search
  • Access EUR-Lex and EU Commission case law
  • See relevant paragraphs highlighted instantly
Start free trial

Similar Documents

Explore similar documents to your case.

We Found Similar Cases for You

Sign up for free to view them and see the most relevant paragraphs highlighted.

NOVARTIS / GLAXOSMITHKLINE ONCOLOGY BUSINESS

M.7275

NOVARTIS / GLAXOSMITHKLINE ONCOLOGY BUSINESS
January 27, 2015
With Google you find a lot.
With us you find everything. Try it now!

I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!

Valentina R., lawyer

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

(1) Novartis AG has entered into an agreement to acquire the business relating to a portfolio of oncology products (excluding manufacturing) from GlaxoSmithKline Plc (the “GSK Oncology Business”), which constitutes a concentration within the meaning of Article 3(1)(b) of Council Regulation (EC) Nº 139/2004.

(2) Novartis is a healthcare company headquartered in Basel (Switzerland), and listed on the SIX Swiss Exchange as well as on the New York Stock Exchange. Novartis is active in five broad areas of healthcare: pharmaceuticals, eye care, generics, Over-the-Counter (“OTC”) and vaccine products.

(3) The GSK Oncology Business is active worldwide in the research, development, and marketing of oncology products for various indications.

(4) The Proposed Transaction forms part of a three-part inter-conditional transaction whereby GSK has agreed to acquire sole control over Novartis’ vaccine business (excluding the influenza business) and GSK and Novartis have agreed to combine their consumer health businesses into a new venture under the sole control of GSK. These parts of the overall transaction constitute a separate concentration and have been notified as Case COMP/M.7276.

EUC

AI-Powered Case Law Search

Query in any language with multilingual search
Access EUR-Lex and EU Commission case law
See relevant paragraphs highlighted instantly

Get Instant Answers to Your Legal Questions

Cancel your subscription anytime, no questions asked.Start 14-Day Free Trial

At Modern Legal, we’re building the world’s best search engine for legal professionals. Access EU and global case law with AI-powered precision, saving you time and delivering relevant insights instantly.

Contact Us

Tivolska cesta 48, 1000 Ljubljana, Slovenia